Track topics on Twitter Track topics that are important to you
Does End-fire Technique Increase Detection Rate Of Prostate Cancer At First Re-biopsy Compared To Side-fire Technique? PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Does End-fire Technique Increase Detection Rate Of Prostate Cancer At First Re-biopsy Compared To Side-fire Technique? articles that have been published worldwide.
We have published hundreds of Does End-fire Technique Increase Detection Rate Of Prostate Cancer At First Re-biopsy Compared To Side-fire Technique? news stories on BioPortfolio along with dozens of Does End-fire Technique Increase Detection Rate Of Prostate Cancer At First Re-biopsy Compared To Side-fire Technique? Clinical Trials and PubMed Articles about Does End-fire Technique Increase Detection Rate Of Prostate Cancer At First Re-biopsy Compared To Side-fire Technique? for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Does End-fire Technique Increase Detection Rate Of Prostate Cancer At First Re-biopsy Compared To Side-fire Technique? Companies in our database. You can also find out about relevant Does End-fire Technique Increase Detection Rate Of Prostate Cancer At First Re-biopsy Compared To Side-fire Technique? Drugs and Medications on this site too.
To determine the minimum number of transperineal prostate mapping biopsies (TPMB) to optimize the prostate cancer detection rate (CDR).
To report the experience, cancer diagnosis rate, complications and patient tolerability of transperineal prostate biopsies (TPBx) in 1287 consecutive patients at risk of prostate cancer (PCa).
The accuracy of needle biopsy for the detection of prostate cancer is limited by well-known sampling errors. Thus, there is an unmet need for a microscopic screening tool that can screen large regions of the prostate comprehensively for cancer. Previous prostate imaging by optical coherence tomography (OCT) have had insufficient resolution for imaging cellular features related to prostate cancer. We have recently developed micro-optical coherence tomography (μOCT) that generates depth-resolved tissue image...
The purpose of this study is to show the performance and evaluate the factors influencing the positivity rate (PR) of commercially produced F-fluciclovine PET/CT in the detection of recurrent prostate cancer in clinical practice. We performed a retrospective cohort study of 152 men who had suspected biochemical recurrence of prostate cancer after receiving initial treatment and underwent fluciclovine PET/CT. PRs were calculated for whole-body, prostate and prostate bed, and extraprostatic locations. The in...
To evaluate the effects of African American (AA) race on the number, location, Prostate Imaging Reporting and Data System (PI-RADS) score, cancer detection rate, and cancer upgrade rate of the regions of interest (ROI) discovered on mltiparametric magnetic resonance imaging (mp-MRI) of the prostate.
Multiparametric magnetic resonance imaging (MRI) enhances detection and risk stratification for significant prostate cancer but is time-consuming (approximately 40 minutes) and expensive. Rapid and simpler (approximately 15-minute) biparametric MRI (bpMRI) using fewer scan sequences could be implemented as a prostate MRI triage test on a larger scale before performing biopsies.
Prostate cancer (PrC) is one of the most common tumors diagnosed in men. The detection rate of localized PrC has been dramatically enhanced by screening and the development of visualization methods. There are currently several techniques for focal treatment available, among which the most interesting in our opinion is high-intensity focused ultrasound (HIFU). Currently, HIFU hemiablation of PrC is not an established treatment, although evidence of its effectiveness and safety is growing. We have been perfor...
Multi-parametric magnetic resonance imaging (mpMRI)-directed biopsy for prostate cancer (PC) diagnosis improves the detection of clinically significant prostate cancer (CSPC) and decreases the rate of over-diagnosis of insignificant disease. The aim of this study was to investigate the value of mpMRI combined with prostate specific antigen density (PSAD) in the decision making related to the biopsy.
Magnetic resonance imaging (MRI) guidance improves the accuracy of prostate biopsy for the detection of clinically significant prostate cancer, but the optimal use of such guidance is not yet clear.
Prostate cancer (PCa) is the most prevalent cancer with a high mortality rate. The early and accurate detection of PCa can significantly reduce mortality and saves lives. Hence, the nanomaterials based electrochemical nano-biosensors for PCa biomarkers will be the excellent alternative for diagnosis, detection and management of disease condition. In this review, we present a concise summary of the latest attainment and advancement in the use of nanoparticles for the diagnosis of PCa biomarkers. This review ...
The advent of targeted prostate biopsies to suspicious lesions based on imaging confers improved detection of clinically significant prostate cancer. The oversampling of these lesions is likely to better represent the cancer grade. However, such grade inflation might lead to the Will Rogers phenomenon. This study aims to investigate whether patients with Gleason 3+4 cancer on transrectal biopsy are upgraded following transperineal MRI-targeted biopsy & whether this has implications for current clinical prac...
Following years of controversy regarding screening for prostate cancer using prostate-specific antigen, evidence evolves towards a more restrained and preference-based use. This study reports the impact of landmark trials and updated recommendations on the incidence rate of prostate cancer screening by Swiss general practitioners.
Prostate-specific antigen (PSA) is an established tumour marker for prostate cancer (PCa). Serum thymidine kinase 1 is a possible new marker for the detection of PCa. The aim of the study was to investigate the diagnostic value of the AroCell TK 210 enzyme-linked immunosorbent assay (ELISA) together with free PSA, [-2]proPSA, and Prostate Health Index (PHI) in differentiating PCa from benign urological conditions.
The last 25 years, the prostate specific antigen (PSA) of the serum is used to diagnose prostate cancer. The experience of applying the PSA test showed its inconsistency as a diagnostic marker due to low cancerspecificity. Along with this, the next wave of biomarkers of prostate cancer appeared, which may supplement or, in due course, replace PSA due to higher sensitivity and cancerspecificity. This expanding panel of biomarkers was supplemented, basically, with new genomic technologies, which allowed to lo...
Prostate-specific membrane antigen (PSMA) PET/CT is increasingly used in patients with biochemically recurrent prostate cancer (BCR), mostly using gallium-68 (Ga)-labelled radiotracers. Alternatively, fluorine-18 (F)-labelled PSMA tracers are available, such as F-DCFPyL, which offer enhanced image quality and therefore potentially increased detection of small metastases. In this study we evaluate the lesion detection efficacy of F-DCFPyL PET/CT in patients with BCR and determine the detection efficacy as a ...
Prostate-specific membrane antigen (PSMA)-targeted PET/CT has become a fundamental tool in the management of patients with prostate cancer, especially to rule out local recurrence after surgery or radiation. However, the assessment of the prostatic fossa is difficult due to the renal excretion of PSMA-targeted radionuclides. PET/CT studies using Ga-PSMA-11 PET/CT and F-PSMA-1007 of a 61-year-old man after radical prostatectomy are presented. This case illustrates that F-PSMA-1007 is an ideal radionuclide fo...
Current knowledge of the validity of registry data on prostate cancer-specific death is limited. We aimed to determine the underlying cause of death among Danish men with prostate cancer, to estimate the level of misattribution of prostate cancer death, and to examine the risk of death from prostate cancer when accounting for competing risk of death.
The aim of the study was to compare the diagnostic accuracy of multiparametric magnetic resonance imaging (mpMRI), multiparametric ultrasound (mpUS) and US/MRI fusion imaging techniques in the detection of prostate cancer.
Prostate cancer (PC) is a multifocal disease. DNA methylation alterations are not restricted to the immediate peritumor environment, but spatially widespread in the adjacent and distant histologically normal prostate tissues. In the current study, we utilized high-throughput methylation arrays to identify epigenetic changes in the urine from men with and without cancer.
This study aimed to evaluate the value of the Young's modulus obtained by transrectal real-time shear wave elastography (SWE) for detection of prostate cancer (PCa).
To examine the long-term outcomes of high dose rate brachytherapy boost (HDR-BT) combined with external beam radiotherapy (EBRT) for intermediate and high-risk prostate cancer patients.
Vitamin K inhibits prostate cancer cells, and an altered expression of vitamin K-dependent proteins in prostate tumors has been linked to their aggressiveness and progression. However, little is known about the effect of vitamin K intake on prostate cancer in human populations.
Endometrial cancer is the most common gynecologic cancer in the United States. However, no early detection test exists for asymptomatic women at average risk for endometrial cancer.
For prostate cancer (PCa) patients, radical prostatectomy (complete removal of the prostate) is the only curative surgical option. To date, there is no clinical technique allowing for real-time assessment of surgical margins to minimize the extent of residual cancer. Here, we present a tissue interrogation technique using a dual excitation wavelength Raman spectroscopy system capable of sequentially acquiring fingerprint (FP) and high wavenumber (HWN) Raman spectra. Results demonstrate the ability of the sy...
To evaluate the predictive value of MRI-defined prostate-specific antigen (PSA) density and MRI interpretation for the detection of clinically significant prostate cancer (PCa).